Radiopharm issues 140M employee incentive options

The 140,028,000 options are subject to transfer restrictions and are not quoted on ASX until those restrictions end.

Rhea-AI Filing Summary

Radiopharm Theranostics Ltd (RADX) reported four directors’ interest notices recording cancellation of listed options. Following the changes, Bruce Goodwin reported indirect holdings of 2,777,778 shares and 1,666,667 options; Ian Turner’s reported totals were 12,763,070 shares and 23,694,015 options; Paul Hopper’s were 150,499,206 shares and 36,826,185 options; and Riccardo Canevari’s were 26,568,875 shares and 161,745,632 options.

The company issued 140,028,000 unquoted options under its employee incentive scheme on October 19, 2026. They are subject to a restriction on transfer and are not quoted on ASX until the restriction ends. The notice lists 30,887,000 options issued to key management personnel Dimitris Voliotis. The issue fell within Listing Rule 7.2 exception 13, so security holder approval under Listing Rule 7.1 was not required.

Key Figures

Employee incentive scheme options issued: 140,028,000 options Options issued to Dimitris Voliotis: 30,887,000 options Ordinary fully paid shares on issue: 4,710,882,790 shares +4 more

7 metrics

Employee incentive scheme options issued 140,028,000 options Issued October 19, 2026

Options issued to Dimitris Voliotis 30,887,000 options Key management personnel recipient

Ordinary fully paid shares on issue 4,710,882,790 shares Listed securities following the reported issue

RADAN options on issue 503,207,525 options Unquoted securities following the reported issue

Ian Turner reported total share holdings 12,763,070 shares Held after the reported change

Ian Turner reported total option holdings 23,694,015 options Held after the reported change

Paul Hopper reported total option holdings 36,826,185 options Held after the reported change

Key Terms

unquoted securities, employee incentive scheme, restriction on transfer, key management personnel (KMP), +1 more

5 terms

unquoted securities technical

"securities issued under an employee incentive scheme"

employee incentive scheme technical

"issued under an employee incentive scheme"

restriction on transfer technical

"subject to a restriction on transfer"

key management personnel (KMP) technical

"issued to key management personnel (KMP)"

Listing Rule 7.2 regulatory

"exception in Listing Rule 7.2"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many unquoted options did Radiopharm Theranostics (RADX) issue?

Radiopharm Theranostics issued 140,028,000 unquoted options on October 19, 2026, under its employee incentive scheme. They are subject to a restriction on transfer and are not quoted on ASX until the restriction ends.

How many options were issued to Dimitris Voliotis?

The notice lists 30,887,000 options issued to Dimitris Voliotis, identified as key management personnel.

Did Radiopharm need security holder approval for the new RADX options?

No. The issue was made under exception 13 of Listing Rule 7.2 and therefore did not need security holder approval under Listing Rule 7.1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/20/2026 - 06:07 AM EDT Accepted by SEC EDGAR 10/20/2026 - 06:07 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2026

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published two announcements (the “Public Notice”) to the Australian Securities Exchange on October 20, 2026 titled:

“Change of Director's Interest Notices x 4”

“Notification regarding unquoted securities - RAD”

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including any exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any registration statement or prospectus under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such registration statement or prospectus.

1

EXHIBITS

Exhibit Number		Description
99.1		Change of Director's Interest Notices x 4
99.2		Notification regarding unquoted securities - RAD

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED
Date: October 20, 2026	By:	/s/ Amritha Sushil
		Amritha Sushil
		Company Secretary

3

Exhibit 99.1

Appendix 3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.             Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Bruce Goodwin
Date of Last Notice:	22 September 2026

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or Indirect Interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Sundial Management Pty Limited of which of which Mr Goodwin is a Director and Shareholder.
Date of change	16 October 2026
No. of securities held prior to change			Shares	Options
		Indirect	2,777,778	2,777,778
Class	Listed Options
Number acquired	Nil
Number disposed	1,111,111 Listed Options, EXP 31 Jul 29, EX $0.018
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.
01/01/2011	Appendix 3Y Page 1

Appendix 3Y

Change of Director’s Interest Notice

No. of securities held after change			Shares	Options
		Indirect	2,777,778	1,666,667
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Cancellation of Listed options

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.
Appendix 3Y Page 2	01/01/2011

Appendix 3Y

Change of Director’s Interest Notice

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.
01/01/2011	Appendix 3Y Page 3

Appendix 3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.        Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Ian Turner
Date of Last Notice:	22 September 2026

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or Indirect Interest	Direct and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Superannuation fund
Date of change	16 October 2026
No. of securities held prior to change			Shares	Options
		Direct	3,752,817	23,179,148
		Indirect	9,010,253	1,625,978
		Total	12,763,070	24,805,126
Class	Listed Options
Number acquired	Nil
Number disposed	1,111,111 Listed Options, EXP 31 Jul 29, EX $0.018
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.
01/01/2011	Appendix 3Y Page 1

Appendix 3Y

Change of Director’s Interest Notice

No. of securities held after change			Shares	Options
		Direct	3,752,817	22,068,037
		Indirect	9,010,253	1,625,978
		Total	12,763,070	23,694,015
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Cancellation of Listed options

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.
Appendix 3Y Page 2	01/01/2011

Appendix 3Y

Change of Director’s Interest Notice

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.
01/01/2011	Appendix 3Y Page 3

Appendix 3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.             Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Paul Hopper
Date of Last Notice:	22 September 2026

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or Indirect Interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	16 October 2026
No. of securities held prior to change			Shares	Options
		Direct	53,900,000	26,142,000
		Indirect	96,599,206	11,795,296
		Total	150,499,206	37,937,296
Class	Listed Options
Number acquired	Nil
Number disposed	1,111,111 Listed Options, EXP 31 Jul 29, EX $0.018
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.
01/01/2011	Appendix 3Y Page 1

Appendix 3Y

Change of Director’s Interest Notice

No. of securities held after change			Shares	Options
		Direct	53,900,000	26,142,000
		Indirect	96,599,206	10,684,185
		Total	150,499,206	36,826,185
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Cancellation of Listed options.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.
Appendix 3Y Page 2	01/01/2011

Appendix 3Y

Change of Director’s Interest Notice

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.
01/01/2011	Appendix 3Y Page 3

Appendix 3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.           Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Riccardo Canevari
Date of Last Notice:	1 October 2026

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or Indirect Interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	16 October 2026
No. of securities held prior to change			Shares	Options
		Direct	23,918,875	163,301,188
		Indirect	2,650,000	-
		Total	26,568,875	163,301,188
Class	Listed Options
Number acquired		Nil
Number disposed		1,555,556 Listed Options, EXP 31 Jul 29, EX $0.018
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.
01/01/2011	Appendix 3Y Page 1

Appendix 3Y

Change of Director’s Interest Notice

No. of securities held after change			Shares	Options
		Direct	23,918,875	161,745,632
		Indirect	2,650,000	-
		Total	26,568,875	161,745,632
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Cancellation of Listed options.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.
Appendix 3Y Page 2	01/01/2011

Appendix 3Y

Change of Director’s Interest Notice

Part 3 – Closed period 

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.
01/01/2011	Appendix 3Y Page 3

Exhibit 99.2

  Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

Announcement Summary

Entity name

RADIOPHARM THERANOSTICS LIMITED

Date of this announcement

Tuesday October 20, 2026

The +securities the subject of this notification are:

+Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

Total number of +securities to be issued/transferred

ASX +security code		Security description		Total number of + securities to be issued/transferred		Issue date
RADAN		OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES		140,028,000		19/10/2026

Refer to next page for full details of the announcement

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 1 / 6

  Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

Part 1 - Entity and announcement details

1.1 Name of entity

RADIOPHARM THERANOSTICS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type	Registration number
ACN	647877889

1.3 ASX issuer code

RAD

1.4 The announcement is

New announcement

1.5 Date of this announcement

20/10/2026

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 2 / 6

  Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code (“existing class”)

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 3 / 6

  Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities in an existing class issued under an +employee incentive scheme

ASX +security code and description

RADAN : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES

Date the +securities the subject of this notification were issued

19/10/2026

Will these +securities rank equally in all respects from their issue date with the existing issued

+securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.

	Name of KMP		Name of registered holder		Number of +securities
	Dimitris Voliotis		Dimitris Voliotis		30,887,000

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Refer to page 33 of the 2025 Notice of Annual General Meeting for the Material terms of the Omnibus Incentive Plan: http s://asx.api.cmfyapp.com/asx-research/1.0/file/2924-03011824-2A1630827&v=undefined

Any other information the entity wishes to provide about the +securities the subject of this notification

n/a

Issue details

Number of +securities

140,028,000

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 4 / 6

  Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity’s current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

ASX +security code and description		Total number of +securities on issue
RADO : OPTION EXPIRING 30-NOV-2026			79,352,040
RAD : ORDINARY FULLY PAID			4,710,882,790
RADOC : OPTION EXPIRING 31-JUL-2029			982,172,830
RADOB : OPTION EXPIRING 31-OCT-2027			1,179,266,658

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description		Total number of +securities on issue
RADAK : OPTION EXPIRING 01-JUN-2027 EX $0.60			1,666,500
RADAAB : WARRANT EXPIRING 31-JUL-2029 EX USD3.79			1,281,646
RADAAC : WARRANT EXPIRING 31-JUL-2029 EX USD3.95			64,082
RADAN : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES			503,207,525
RADAJ : OPTION EXPIRING 01-JUL-2027 EX $0.17			12,425,675
RADAF : OPTION EXPIRING 25-NOV-2026 RESTRICTED			8,666,678
RADAG : OPTION EXPIRING 25-NOV-2026 EX $0.60			5,066,672
RADAI : OPTION EXPIRING 27-MAY-2027 EX $0.60			740,000
RADAP : OPTION EXPIRING 24-APR-2028 EX $0.09			8,955,224

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 5 / 6

  Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 6 / 6

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 CHANGE OF DIRECTOR'S INTEREST NOTICES X 4 202.4 KB
• EX-99.2 NOTIFICATION REGARDING UNQUOTED SECURITIES - RAD 36.0 KB